^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
Published date:
06/12/2020
Excerpt:
TP53 deficiency decreased sensitivity to VEN . Additionally, the sensitivity to the BH4 domain BCL-2 inhibitor BDA-366 was significantly reduced upon knockout of p53…Although VEN is mediating apoptosis in a TP53 independent manner, it seems to be less effective in TP53 deficient cells.
